Karyopharm Therapeutics | KPTI - Trade Debtors


Karyopharm Therapeutics reported $31.78M in Trade Debtors for its fiscal quarter ending in September of 2024.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Abbott USD 10.4B 166M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
BioCryst Pharmaceuticals USD 79.07M 6.61M Dec/2024
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Eli Lilly USD 19.46B 2.25B Sep/2025
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Incyte USD 1.02B 128.52M Dec/2025
J&J USD 17.61B 235M Sep/2025
Karyopharm Therapeutics USD 31.78M 6.82M Sep/2024
MacroGenics USD 69.23M 56.7M Sep/2025
Merck USD 12.12B 596M Sep/2025
Nektar Therapeutics USD 0 2.9M Sep/2024
Novartis USD 8.98B 192M Sep/2025
Novartis USD 8.98B 192M Sep/2025
Pfizer USD 18.12B 2.02B Sep/2025
Regeneron Pharmaceuticals USD 5.74B 54M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sangamo BioSciences USD 581K 110K Jun/2024
Takeda JPY 757.92B 55.68B Dec/2025
Tectonic Therapeutic USD 0 270K Dec/2023
TG Therapeutics USD 265.38M 33.86M Sep/2025
Ultragenyx Pharmaceutical USD 112.54M 11.92M Sep/2025
Xencor USD 29.3M 7.49M Dec/2025